### Highlights of This Issue  3359

#### SPECIAL FEATURES

**CCR Translations**

3361  **MET as a Target in Papillary Renal Cell Carcinoma**  
André P. Fay, Sabina Signoretti, and Toni K. Choueiri  
See related article, p. 3411

**CCR Perspectives in Drug Approval**

3364  **U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009**  
Sonia K. Morgan-Linnell, David J. Stewart, and Razelle Kurzrock

**Statistics in Clinical Cancer Research**

3371  **Blocking and Randomization to Improve Molecular Biomarker Discovery**  
Li-Xuan Qin, Qin Zhou, Faina Bogomolniy, Liliana Villafania, Narciso Olvera, Magali Cavatore, Jaya M. Satagopan, Colin B. Begg, and Douglas A. Levine

**Molecular Pathways**

3379  **Molecular Pathways: CDK4 Inhibitors for Cancer Therapy**  
Mark A. Dickson

3384  **Molecular Pathways: Niches in Metastatic Dormancy**  
Kenji Yamoto, Matthew R. Eber, Janice E. Berry, Russell S. Taichman, and Yusuke Shiozawa

**Review**

3390  **Infusions of Allogeneic Natural Killer Cells as Cancer Therapy**  
Wing Leung

### HUMAN CANCER BIOLOGY

3401  **Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions**  
Yong-Chen Lu, Xin Yao, Jessica S. Crysta, Yong F. Li, Mona El-Gamil, Colin Gross, Lindy Davis, Mark E. Dudley, James C. Yang, Yardena Samuels, Steven A. Rosenberg, and Paul F. Robbins

3411  **MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of PRCC with CGH Array and Matching Gene Expression Array**  
Laurence Albisig, Justine Guegan, Audrey Le Formal, Virginie Verkarre, Nathalie Rioux-Leclercq, Mathilde Sibony, Jean-Christophe Bernhard, Philippe Camparo, Zahara Merabet, Vincent Molinie, Yves Allory, Cedric Orear, Sophie Couvé, Sophie Gad, Jean-Jacques Patard, and Bernard Escudier  
See related article, p. 3361

3422  **Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer**  
Natalie Hartmann, Nathalia A. Giese, Thomas Gielse, Isabel Poschke, Rienk Oftringa, Jens Werner, and Eduard Ryschich

3434  **Overexpression of Sirt7 Exhibits Oncogenic Property and Serves as a Prognostic Factor in Colorectal Cancer**  
Hongyan Yu, Wen Ye, Jiangxue Wu, Xiangqi Meng, Ran-yi Liu, Xiaofang Ying, Yi Zhou, Hui Wang, Changchuan Pan, and Wenlin Huang

### CANCER THERAPY: PRECLINICAL

3446  **Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma**  
Mohammad Atefi, Earl Avramis, Amanda Lassen, Deborah J.L. Wong, Lidia Robert, David Foulad, Michael Cermiglia, Bjorn Titze, Thinle Chodon, Thomas G. Graeber, Begonya Comin-Anduix, and Antoni Ribas
Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)

Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis
Dongshi Chen, Liang Wei, Jian Yu, and Lin Zhang

Synergistic Anticancer Effects of Pam3CSK4 and Ara-C on B-Cell Lymphoma Cells
Sae-Kyung Lee, Jyh Y. Chwee, Cheryl A.P. Ma, Nina Le Bert, Caleb W. Huang, and Stephan Gasser

Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage
Giannaria Liccardi, John A. Hartley, and Daniel Hochhauser

Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

Old Drug New Use—Amoxapine and Its Metabolites as Potent Bacterial β-Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity
Ren Kong, Timothy Liu, Xiaoping Zhu, Syed Ahmad, Alfred L. Williams, Alexandra T. Phan, Hong Zhao, John E. Scott, Li-Ai Yeh, and Stephen T.C. Wong

In Vivo Fluorescence Lifetime Imaging for Monitoring the Efficacy of the Cancer Treatment
Yasaman Ardestirpour, Victor Chernomordik, Moinuddin Hassan, Rafal Zielinski, Jacek Capala, and Amir Gandjbakhche

Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18F-Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study
Katja Pinker, Wolfgang Bogner, Pascal Bälzter, Georgios Karanikas, Heinrich Magometschnigg, Peter Brader, Stephan Gruber, Hubert Bickel, Peter Dusby, Zsuzsanna Bago-Horváth, Rupert Bartsh, Michael Weber, Siegfried Trattnig, and Thomas H. Helbich

Treatment Response Evaluation Using 18F-FDOPE PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy
Johannes Schwarzengger, Johannes Czernin, Whitney B. Pope, Tristan Grogan, David Elashoff, Cheri Geist, Daniel H.S. Silverman, Michael E. Phelps, and Wei Chen

Variability in Assessing Treatment Response: Metastatic Colorectal Cancer as a Paradigm
Binsheng Zhao, Shing M. Lee, Hyun-Ju Lee, Yongqiang Tan, Jing Qi, Thorsten Persiex, David P. Mozley, and Lawrence H. Schwartz

TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance
Laxmi Silwal-Pandit, Hans Kristian Moen Vollan, Suet-Feung Chin, Oscar M. Rueda, Steven McKinney, Tomo Osako, David A. Quigley, Vessela N. Kristensen, Samuel Aparicio, Anne-Lise Berresen-Dale, Carlos Caldas, and Anita Langerod

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling, Eyas Raddad, John Polzer, Stephanie Roberson, John R. Stille, Mansoor Saleh, and Donald Thornton

Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q- Patients with MDS and AML
Katharina Blatt, Harald Herrmann, Gregor Hoermann, Michael Willmann, Sabine Cerny-Reiterer, Irina Sadovnik, Susanne Herndlhofer, Berthold Streueler, Werner Rabitsch, Wolfgang R. Speer, Matthias Mayerhofer, Thomas Rulicke, and Peter Valent
3603 Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
Ian Judson, Michelle Scurr, Kate Gardner, Elizabeth Barquin, Marcelo Marotti, Barbara Collins, Helen Young, Juliane M. Jürgensmeier, and Michael Leahy

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

3613 Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
Mikihiro Kohno, Tatsuro Okamoto, Kenichi Suda, Mototsugu Shimokawa, Hirokazu Kitahara, Shinichiro Shimamatsu, Hideyuki Konishi, Tsukihisa Yoshida, Mitsuhiro Takenoyama, Tokujiro Yano, and Yoshihiko Maehara

LETTERS TO THE EDITOR

3623 SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Letter
Abolfazl Avan, Mina Maftouh, Amir Avan, Carmelo Tibaldi, Paolo A. Zucali, and Elisa Giovannetti

3625 SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Response
Qianxia Li, Huihua Xiong, and Xianglin Yuan

ABOUT THE COVER

Loss of S6 phosphorylation as a biomarker of response to PI3K/mTOR pathway inhibition. The representative image shows immunohistochemical staining for phosphorylated S6 protein (ser235-236) in SUM190 breast cancer cell line xenografts treated with the pan-PI3K inhibitor BKM120. For details, see the article by O’Brien and colleagues on page 3507 of this issue.
Clinical Cancer Research

20 (13)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/13

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.